CIK Cell Therapy
CIK cell therapy is a form of adoptive immunotherapy that uses a mixed population of immune cells — expanded and activated outside the body using cytokine stimulation — to strengthen the immune system's ability to identify and destroy tumour cells. CIK cells share functional characteristics of both T-cells and NK cells, giving them a broader range of tumour-targeting capability than either cell type alone.
At Regenex Asia, CIK therapy is manufactured in our cGMP-certified laboratory and applied as a supportive cancer immunotherapy — designed to complement conventional oncology treatments, not replace them.
What Are Cytokine-Induced Killer Cells?
CIK cells are a heterogeneous population of immune cells generated by culturing peripheral blood mononuclear cells (PBMCs) — taken from a blood sample — with a cocktail of cytokines including interferon-gamma (IFN-γ), anti-CD3 antibody and interleukin-2 (IL-2). This stimulation process, conducted over approximately 14–21 days, expands and activates a mixed cell population dominated by CD3+ CD56+ cells — a phenotype that combines T-cell and NK cell characteristics.
The result is a cell product that can recognise and kill tumour cells through multiple mechanisms: MHC-restricted killing (like T-cells), MHC-unrestricted killing (like NK cells) and antibody-dependent cellular cytotoxicity. This dual-mechanism approach gives CIK cells a broader spectrum of anti-tumour activity than either T-cells or NK cells alone.
Unlike CAR-T cells, CIK cells are not genetically engineered. Unlike purified NK cell products, CIK cultures contain a mixed immune cell population. This makes CIK therapy less precisely targeted than CAR-T but more broadly reactive than single-cell-type approaches — and significantly simpler to manufacture.
Where CIK Fits Among Cancer Immunotherapies
| CIK Cells | NK Cells | CAR-T Cells | |
|---|---|---|---|
| Cell population | Mixed (CD3+ CD56+ dominant) | Purified NK (CD56+ CD3−) | Engineered T-cells with CAR |
| Genetic engineering | None | None | Yes — CAR gene inserted |
| Tumour targeting | Broad — multiple mechanisms | Broad — "missing self" | Highly specific — single antigen |
| Manufacturing | Moderate complexity | Moderate complexity | High complexity |
| Role | Supportive immunotherapy | Supportive + viral | Targeted therapy for blood cancers |
| Risk profile | Generally well-tolerated | Generally well-tolerated | CRS and ICANS risk |
CIK, NK and CAR-T therapies are not interchangeable — they serve different clinical roles. Your oncologist can help determine which approach is most appropriate.
How CIK Cell Therapy Is Manufactured and Administered
Blood Collection
A blood sample is collected from the patient (autologous protocol) or from a screened, healthy donor (allogeneic protocol). The peripheral blood mononuclear cells (PBMCs) are isolated from the sample for processing.
Cytokine Stimulation & Expansion (14–21 days)
The isolated PBMCs are cultured in our cGMP clean room with a defined cytokine cocktail — interferon-gamma, anti-CD3 antibody and interleukin-2 — that selectively expands and activates the CIK cell population. The culture is monitored for cell growth, viability and phenotype throughout.
Quality Testing & Release
Every batch undergoes: cell count and viability testing, phenotype analysis (confirming CD3+ CD56+ population), sterility testing, endotoxin and mycoplasma screening, and a cytotoxicity assay confirming functional tumour-killing ability. Each batch receives a Certificate of Analysis.
Patient Administration
CIK cells are administered via intravenous (IV) infusion. Treatment is typically delivered as a series of infusions over a defined period, coordinated with the patient's broader oncology treatment plan. The treating oncologist determines timing, dosage and integration with other therapies.
When CIK Cell Therapy Is Used
CIK cell therapy is applied as a supportive immunotherapy in cancer treatment — typically in one of three clinical contexts:
Alongside conventional treatment
CIK therapy may be administered during or between cycles of chemotherapy to provide ongoing immune support while the patient is receiving standard oncology care. The goal is to supplement the immune system's anti-tumour activity during a period when chemotherapy may be suppressing overall immune function.
After completing conventional treatment
For patients who have completed first-line treatment (surgery, chemotherapy, radiation) and achieved remission, CIK therapy may be used as a consolidation strategy — aiming to strengthen immune surveillance and reduce the risk of cancer recurrence.
In advanced or refractory cases
For patients with advanced or treatment-resistant cancers, CIK therapy may be considered as part of a multi-modal immunotherapy approach alongside NK cell therapy, targeted therapy or other supportive interventions.
Cancers Where CIK Therapy Has Been Investigated
CIK cell therapy has been studied across a range of cancer types in published clinical research, including:
The evidence base varies by cancer type. The strongest evidence supports CIK therapy as a complement to conventional treatment rather than a standalone intervention.
Is CIK Cell Therapy Safe?
CIK cell therapy is generally well-tolerated with a favourable safety profile compared to more intensive immunotherapies such as CAR-T. Because CIK cells are not genetically engineered and rely on natural immune mechanisms, the risk of severe immune reactions such as cytokine release syndrome (CRS) is considerably lower.
Potential side effects may include:
- Mild fever, chills or fatigue following infusion — typically resolving within 24–48 hours
- Transient flu-like symptoms
- Mild infusion-related reactions (nausea, headache)
- Rare allergic reactions
Serious adverse events are uncommon. As with all immune cell therapies, patients are monitored during and after infusion. All potential risks are discussed with the patient and their oncologist during the pre-treatment consultation.
CIK vs NK Cell Therapy: Choosing the Right Supportive Immunotherapy
Both CIK and NK cell therapy function as supportive cancer immunotherapies — but they differ in cell population, mechanism and clinical context.
Choose CIK when:
- A mixed immune cell population with T-cell and NK cell characteristics is preferred
- The plan calls for broad-spectrum immune support alongside conventional therapy
- Solid tumours where CIK has published evidence (liver, gastric, colorectal, lung, renal)
Choose NK when:
- A purified, single-cell-type product with defined phenotype is preferred
- Blood cancers, HIV or hepatitis B are the clinical context
- Maximum NK cell cytotoxic potency is the clinical goal
In some treatment plans, CIK and NK cell therapy may be used in combination or sequentially. Your oncologist is the best person to determine the appropriate approach.
Learn more about NK Cell TherapyFrequently Asked Questions About CIK Cell Therapy
What does CIK stand for?
CIK stands for Cytokine-Induced Killer. The name describes the manufacturing process: immune cells are induced (stimulated) to develop enhanced killing capability using cytokines (immune signalling molecules) in a laboratory setting.
Is CIK therapy a cure for cancer?
No. CIK cell therapy is a supportive immunotherapy designed to strengthen the immune system's anti-tumour response. It complements conventional cancer treatment — it does not replace surgery, chemotherapy, radiation or other standard oncology therapies.
How is CIK different from CAR-T?
CAR-T cells are genetically engineered to target a specific cancer antigen — highly precise but carry risks of CRS and ICANS. CIK cells are not genetically engineered — they are naturally expanded immune cells with broader but less targeted anti-tumour activity. CIK therapy is simpler to manufacture, generally better tolerated and applicable across a wider range of cancer types as a supportive treatment.
How many CIK infusions are needed?
Treatment protocols vary by cancer type and clinical context. CIK therapy is typically administered as a series of infusions — commonly 3–6 infusions over several weeks — coordinated with the patient's broader treatment plan. Your oncologist will determine the appropriate schedule.
How much does CIK therapy cost?
We do not publish pricing. Costs vary based on the protocol, number of infusions and clinical context. A detailed treatment proposal is provided after your medical assessment.
Related Therapies
NK Cell Therapy
Purified natural killer cell immunotherapy for cancer support and viral immune reconstitution. The closest sibling to CIK therapy — often compared when planning supportive immunotherapy protocols.
CAR-T Cell Therapy
Genetically engineered T-cell therapy for specific relapsed/refractory blood cancers. The most targeted cancer immunotherapy in our portfolio.
Stem Cell Therapy (MSC)
Regenerative stem cell therapy for tissue repair and immune modulation. A different treatment category — relevant for patients managing treatment side effects or seeking post-cancer regenerative support.
Discuss Whether CIK Therapy May Support Your Oncology Treatment Plan
CIK cell therapy is always considered in the context of your broader cancer treatment. Our medical team works alongside your oncologist to assess whether CIK therapy is an appropriate supportive addition to your care.